Technical Perspectives on Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem

Tuesday, March 27, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 27, 2018 /PRNewswire/ -- strives to bring the best free research to the investment

community.  Today we are offering reports on TSRO, TRVN, VNDA, and VSTM which can be accessed for free by signing up to has initiated research coverage on Tesaro Inc. (NASDAQ: TSRO), Trevena
Inc. (NASDAQ: TRVN), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Verastem Inc. (NASDAQ: VSTM). These stocks belong to the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. All you have to do is sign up today for this free limited time offer by clicking the link below.


Shares in Waltham, Massachusetts headquartered Tesaro Inc. saw a decline of 2.24%, ending Monday's trading session at $59.03. The stock recorded a trading volume of 1.34 million shares, which was higher than its three months average volume of 1.16 million shares. The Company's shares are trading 6.49% below their 50-day moving average. Moreover, shares of Tesaro have a Relative Strength Index (RSI) of 41.23.  

On February 28th, 2018, research firm Barclays reiterated its 'Equal Weight' rating on the Company's stock with a decrease of the target price from $135 a share to $90 a share.

On March 14th, 2018, Tesaro, an oncology-focused biopharmaceutical company which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, announced that data for ZEJULA, TSR-042 (anti-PD-1 antibody), and the Company's immuno-oncology portfolio will be presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting, being held from April 14th, 2018 to April 18th, 2018 in Chicago. The Company will be at Booth #1645. Get the full research report on TSRO for free by clicking below at:


Chesterbrook, Pennsylvania headquartered Trevena Inc.'s stock rose 2.33%, closing the day at $1.76 with a total trading volume of 652,924 shares. The Company's shares have advanced 2.33% in the past month and 10.69% in the previous three months. The stock is trading 0.70% above its 50-day moving average. Additionally, shares of Trevena, which develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 46.81. 

On March 20th, 2018, Trevena announced that it will be presenting at the Needham & Company 17th Annual Healthcare Conference on March 27th, 2018, at 2:30 p.m. EDT in New York. A live audio webcast of the presentation will be available under the Investor section of the Company's website. Access the free research report on TRVN now by signing up at:

Vanda Pharmaceuticals

On Monday, shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. recorded a trading volume of 695,682 shares. The stock ended the day 1.48% higher at $17.10. The Company's shares have advanced 14.38% in the previous three months and 18.34% over the past year. The stock is trading above its 50-day and 200-day moving averages by 0.67% and 6.97%, respectively. Furthermore, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 41.34.  

On March 15th, 2018, Vanda Pharma announced the sale of 5,500,000 shares of its common stock in an underwritten public offering at a price to the public of $17.00 per share. The gross offering proceeds to the Company from the sale of the shares are expected to be approximately $93.5 million. After deducting underwriting discounts and commissions and other estimated offering expenses, the net offering proceeds to the Company are expected to be approximately $87.6 million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VNDA at:


Needham, Massachusetts headquartered Verastem Inc.'s stock dropped slightly by 0.32%, finishing yesterday's session at $3.10 with a total trading volume of 504,672 shares. The Company's shares have advanced 1.64% in the previous three months and 86.75% over the past year. The stock is trading below its 50-day moving average by 5.25%. Additionally, shares of Verastem, which focuses on discovering and developing drugs for the treatment of cancer, have an RSI of 42.77.  

On March 08th, 2018, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $15 per share.

On March 14th, 2018, Verastem announced that the Company will present at the 17th Annual Needham Healthcare Conference on March 27th, 2018, at 5:00 p.m. in New York City. A live webcast of the presentation will be available under the investors section of the Company's website. Aspiring Member, please take a moment to register below for your free research report on VSTM at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Cision View original content:

SOURCE Morris Capital Inc

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store